The metastatic potential of canine mammary tumours can be assessed by mRNA expression analysis of connective tissue modulators

Veterinary and Comparative Oncology

Volumn 11, Issue 1, 2013, Pages 70-85

  Lamp, O ^a   Honscha, K U ^a   Schweizer, S ^a   Heckmann, A ^a   Blaschzik, S ^a   Einspanier, A ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Dog; Mammary tumour; PCR; Prognosis; Relaxin; RXFP1

Indexed keywords

DEOXYRIBONUCLEASE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; MESSENGER RNA; RECEPTOR; RELAXIN; RELAXIN RECEPTORS;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION;

ANIMALS; DEOXYRIBONUCLEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 2; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; REVERSE TRANSCRIPTION; RNA, MESSENGER;

CANIDAE; CANIS FAMILIARIS;

EID: 84873747711     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00303.x     Document Type: Article

References (65)

1. Dorn CR, Taylor DON, Schneide R, Hibbard HH and Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties California II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 1968; 40: 307-318.
2. Brodey RS, Goldschmidt MH and Roszel JR. Canine mammary-gland neoplasms. Journal of the American Animal Hospital Association 1983; 19: 61-90.
3. Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW and Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. Journal of Veterinary Internal Medicine 2003; 17: 102-106.
4. st edn., Washington DC, Armed Forces Institute of Pathology, 1999.
5. st edn., Geneva, World Health Organization, 1980: 21-25.
6. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gaertner F and Gruber AD. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Veterinary Pathology 2011; 48: 98-116.
7. Rivera P and von Euler H. Molecular biological aspects on canine and human mammary tumors. Veterinary Pathology 2011; 48: 132-146.
8. Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G, Trumper L and Einspanier A. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Research and Treatment 2004; 87: 157-166.
9. Silvertown JD, Geddes BJ and Summerlee AJ. Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 2003; 144: 3683-3691.
10. Binder C, Hagemann T, Husen B, Schulz M and Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Molecular Human Reproduction 2002; 8: 789-796.
11. Radestock Y, Hoang-Vu C and Hombach-Klonisch S. Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Research 2008; 10: 15.
12. Chakraborti S, Mandal M, Das S, Mandal A and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry 2003; 253: 269-285.
13. Papparella S, Restucci B, Maiolino P and De VG. Immunohistochemical distribution of type IV collagenase in normal, dysplastic and neoplastic canine mammary gland. Journal of Comparative Pathology 1997; 117: 277-282.
14. Papparella S, Restucci B, Paciello O and Maiolino P. Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. Journal of Comparative Pathology 2002; 126: 271-276.
15. Yokota H, Kumata T, Taketaba S, Kobayashi T, Moue H, Taniyama H, Hirayama K, Kagawa Y, Itoh N, Fujita O, Nakade T and Yuasa A. High expression of 92 kDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochimica et Biophysica Acta 2001; 1568: 7-12.
16. Hirayama K, Yokota H, Onai R, Kobayashi T, Kumata T, Kihara K, Okamoto M, Sako T, Nakade T, Izumisawa Y and Taniyama H. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. Journal of Comparative Pathology 2002; 127: 249-256.
17. Kawai K, Uetsuka K, Doi K and Nakayama H. The activity of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. The Journal of Veterinary Medical Science 2006; 68: 105-111.
18. Vinothini G, Balachandran C and Nagini S. Evaluation of molecular markers in canine mammary tumors: correlation with histological grading. Oncology Research 2009; 18: 193-201.
19. Lamp O, Honscha KU, Jakob J, Lamp J, Schweizer S, Reischauer A, Gottschalk J, Hahn A, Ebert M, Rothemund S, Blaschzik S and Einspanier A. Investigation of the local expression of the relaxin system in canine mammary tumours. Reproduction in Domestic Animals 2009; 44: 224-229.
20. Schweizer S, Lamp O, Reischauer A, Lamp J, Blaschzik S, Grevel V and Einspanier A. Investigation of the plasma relaxin levels in bitches with mammary gland tumours as a potential prognostic marker. Reproduction in Domestic Animals 2007; 42(Suppl. 1): 29.
21. Clemente M, Perez-Alenza MD and Pena L. Metastasis of canine inflammatory versus non-inflammatory mammary tumours. Journal of Comparative Pathology 2010; 143:157-163.
22. Einspanier A, Bunck C, Salpigtidou P, Marten A, Fuhrmann K, Hoppen HO and Gunzel-Apel AR. Relaxin: ein wichtiger Graviditatsindikator bei der Hundin [Relaxin: an important indicator of canine pregnancy]. Deutsche Tierarztliche Wochenschrift 2002; 109: 8-12.
23. Kaskous S, Gottschalk J, Hippel T and Grun E. The behavior of growth-influencing and steroid hormones in the blood plasma during pregnancy of Awassi sheep in Syria. Berlin Munchner Tierarztliche Wochenschrift 2003; 116: 108-116.
24. Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A and Sterner-Kock A. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Veterinary Pathology 2006; 43: 934-942.
25. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R and Leunissen JAM. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Research 2007; 35: W71-W74.
26. Altschul SF, Madden TL, Schaffer AA, Zhang JH, Zhang Z, Miller W and Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research 1997; 25: 3389-3402.
27. Pattyn F, Speleman F, De Paepe A and Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Research 2003; 31: 122-123.
28. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ and Moorman AF. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Research 2009; 37: e45.
29. Brinkhof B, Spee B, Rothuizen J and Penning LC. Development and evaluation of canine reference genes for accurate quantification of gene expression. Analytical Biochemistry 2006; 356: 36-43.
30. Andersen CL, Jensen JL and Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research 2004; 64: 5245-5250.
31. Ivell R, Balvers M, Pohnke Y, Telgmann R, Bartsch O, Milde-Langosch K, Bmberger AM and Einspanoier A. Immunoexpression of the relaxin receptor LGR7 in breast and uterine tissues of humans and primates. Reproductive Biology and Endocrinology 2003; 1: 114. DOI: 10.1186/14777827-1-114.
32. Steinetz BG, Goldsmith LT, Hasan SH and Lust G. Diurnal-variation of serum progesterone, but not relaxin, prolactin or estradiol-17-beta in the pregnant bitch. Endocrinology 1990; 127: 1057-1063.
33. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G and Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB Journal 2001; 15: 2187-2195.
34. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD and Hsueh AJ. Activation of orphan receptors by the hormone relaxin. Science 2002; 295: 671-674.
35. Pukrop T, Bleckmann A, Einspanier A and Binder C. Rapid progression of hormone receptor-negative breast cancer concomitant with ovarian stimulation-a paradoxon? Annals of Oncology 2009; 20: 2020-2022.
36. Bani D, Riva A, Bigazzi M and Sacchi TB. Differentiation of breast-cancer cells in-vitro is promoted by the concurrent influence of myoepithelial cells and relaxin. British Journal of Cancer 1994; 70: 900-904.
37. st edn., Berlin, Springer-Verlag, 2007: 104-118.
38. Steinetz BG, Goldsmith LT, Harvey HJ and Lust G. Serum relaxin and progesterone concentrations in pregnant, pseudopregnant, and ovariectomized, progestin-treated pregnant bitches: detection of relaxin as a marker of pregnancy. American Journal of Veterinary Research 1989; 50: 68-71.
39. Klonisch T, Hombach-Klonisch S, Froehlich C, Kauffold J, Steger K, Steinetz BG and Fischer B. Canine preprorelaxin: nucleic acid sequence and localization within the canine placenta. Biology of Reproduction 1999; 60: 551-557.
40. Tsutsui T and Stewart DR. Determination of the source of relaxin immunoreactivity during pregnancy in the dog. Journal of Veterinary Medical Science 1991; 53: 1025-1029.
41. Yamagami T, Kobayashi T, Takahashi K and Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. Journal of Veterinary Medical Science 1996; 58: 1079-1083.
42. Bostock DE. Canine and feline mammary neoplasms. British Veterinary Journal 1986; 142: 506-515.
43. Sorensen KC, Newman RG, Kitchell BE, Schaeffer DJ and Siegel AM. Isolation, characterization, and expression of stromelysin-1 in primary tumors of dogs. American Journal of Veterinary Research 2005; 66: 1526-1535.
44. Unemori EN and Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. Journal of Biological Chemistry 1990; 265: 10681-10685.
45. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME and Amento EP. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. Journal of Clinical Investigation 1996; 98: 2739-2745.
46. Palejwala S, Stein DE, Weiss G, Monia BP, Tortoriello D and Goldsmith LT. Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology 2001; 142: 3405-3413.
47. Henneman S, Bildt MM, Degroot J, Kuijpers-Jagtman AM and Von den Hoff JW. Relaxin stimulates MMP-2 and alpha-smooth muscle actin expression by human periodontal ligament cells. Archives of Oral Biology 2008; 53: 161-167.
48. Lowndes K, Amano A, Yamamoto SY and Bryant-Greenwood GD. The human relaxin receptor (LGR7): expression in the fetal membranes and placenta. Placenta 2006; 27: 610-618.
49. Mazella J, Tang M and Tseng L. Disparate effects of relaxin and TGF beta 1: relaxin increases, but TGF beta 1 inhibits, the relaxin receptor and the production of IGFBP-1 in human endometrial stromal/decidual cells. Human Reproduction 2004; 19: 1513-1518.
50. Halls ML and Cooper DMF. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex. EMBO Journal 2010; 29: 2772-2787.
51. Callander GE, Thomas WG and Bathgate RAD. Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment. American Journal of Physiology-Cell Physiology 2009; 296: C1058-C1066.
52. Kong RCK, Shilling PJ, Lobb DK, Gooley PR and Bathgate RAD. Membrane receptors: structure and function of the relaxin family peptide receptors. Molecular and Cellular Endocrinology 2010; 320: 1-15.
53. Simon D, Schoenrock D, Nolte I, Baumgartner W, Barron R and Mischke R. Cytologic examination of fine-needle aspirates from mammary gland tumors in the dog: diagnostic accuracy with comparison to histopathology and association with postoperative outcome. Veterinary Clinical Pathology 2009; 38: 521-528.
54. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J and Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 2009; 55: 611-622.
55. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002; 3:research0034.1-0034.11
56. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM and Agoulnik AI. Relaxin promotes prostate cancer progression. Clinical Cancer Research 2007; 13: 1695-1702.
57. Hossain MA, Samuel CS, Binder C, Hewitson TD, Tregear GW, Wade JD and Bathgate RAD. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist. Amino Acids 2010; 39: 409-416.
58. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JCH, Summerlee AJS and Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB Journal 2007; 21: 754-765.
59. Chang CC, Tsai MH, Liao JW, Chan JPW, Wong ML and Chang SC. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. Journal of the American Veterinary Medical Association 2009; 235: 391-396.
60. Manee-in S, Srisuwatanasagul S, Lohachit C and Sirivaidyapong S. The number of ERα and PR in the mammary glands of bitches with and without tumor mass using immunohistochemical assay. Comparative Clinical Pathology 2009; 18: 221-227.
61. Martin de Las Mulas J, Millan Y and Dios R. A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Veterinary Pathology 2005; 42: 200-212.
62. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM and Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Veterinary Pathology 2000; 37: 239-247.
63. Alarid ET, Bakopoulos N and Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Molecular Endocrinology 1999; 13: 1522-1534.
64. Lange CA, Shen TJ and Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 1032-1037.
65. Nawaz Z, Lonard DM, Dennis AP, Smith CL and O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 1858-1862.